Akebia Therapeutics, Inc. (AKBA)
0.4013
-0.02
(-5.69%)
USD |
NASDAQ |
Nov 06, 16:00
0.4065
+0.01
(+1.30%)
After-Hours: 20:00
Akebia Therapeutics Research and Development Expense (Annual) : 61.09M for Dec. 31, 2025
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | 61.09M |
| December 31, 2024 | 31.99M |
| December 31, 2023 | 61.49M |
| December 31, 2022 | 128.33M |
| December 31, 2021 | 145.92M |
| December 31, 2020 | 216.41M |
| December 31, 2019 | 322.97M |
| December 31, 2018 | 291.01M |
| Date | Value |
|---|---|
| December 31, 2017 | 230.89M |
| December 31, 2016 | 115.48M |
| December 31, 2015 | 42.72M |
| December 31, 2014 | 25.23M |
| December 31, 2013 | 10.78M |
| December 31, 2012 | 5.632M |
| December 31, 2011 | 12.94M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| Heron Therapeutics, Inc. | 12.43M |
| Tonix Pharmaceuticals Holding Corp. | 44.49M |
| Karyopharm Therapeutics, Inc. | 125.32M |
| Minerva Neurosciences, Inc. | 5.760M |
| Corbus Pharmaceuticals Holdings, Inc. | 70.10M |